Core Viewpoint - The acquisition of Pengli Bio by Aopumai through a "share issuance + cash" method has been approved, marking the first A-share transaction to implement both "installment payment for restructuring shares" and "lock-up period linked to private equity funds" since the introduction of the "six merger rules" [2][3] Group 1 - The transaction breaks the traditional "one-time payment" model, with Aopumai initially paying only 69.13% of the shares, while the remaining portion is linked to performance targets and will be paid in three installments [2] - The "installment payment" approach mitigates risks associated with high premium valuations and performance commitments, aligning the interests of the acquired company's core team with the long-term development of the listed company [2][3] - The "lock-up period linked to private equity funds" allows four private equity firms to reduce their lock-up period from 12 months to 6 months, enhancing the flexibility of risk capital exit and encouraging more active participation in industrial mergers [3] Group 2 - Aopumai's acquisition employs a differentiated pricing mechanism, where the price per share varies based on shareholder type and investment cost, with valuations of 1.23 billion yuan for the controlling shareholder, 1.32 billion yuan for the management team, and 1.55 billion yuan for financial investors [3][4] - The differentiated pricing accommodates the varying demands of different capital backgrounds, addressing the challenges of achieving consensus among multiple shareholders in merger negotiations [4] - The case of Aopumai serves as a reference for improving merger success rates by utilizing "installment payments + differentiated pricing + lock-up period linkage," shifting the focus from transaction-oriented to governance-oriented approaches [5]